---
title: "ARGX: Efgartigimod achieved significant, sustained improvement in autoimmune myositis in Phase 3"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296061848.md"
description: "The ALKIVIA Phase 3 trial showed that efgartigimod significantly improved disease activity in autoimmune myositis, meeting its primary endpoint and demonstrating early, sustained, and multidimensional benefits across IMNM and DM, with a favorable safety profile.Original document: argenx SE [ARGX] Press release — Aug. 17 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-17T06:01:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296061848.md)
  - [en](https://longbridge.com/en/news/296061848.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296061848.md)
---

# ARGX: Efgartigimod achieved significant, sustained improvement in autoimmune myositis in Phase 3

The ALKIVIA Phase 3 trial showed that efgartigimod significantly improved disease activity in autoimmune myositis, meeting its primary endpoint and demonstrating early, sustained, and multidimensional benefits across IMNM and DM, with a favorable safety profile.

Original document: argenx SE \[ARGX\] Press release — Aug. 17 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)

## Related News & Research

- [Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositis](https://longbridge.com/en/news/296078728.md)
- [Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint](https://longbridge.com/en/news/296059044.md)
- [Toth Financial Advisory Corp Boosts Stock Holdings in argenex SE $ARGX](https://longbridge.com/en/news/295778295.md)
- [$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296119451.md)
- [Argenx Shares Rise After Positive Results From Phase 3 Study of Efgartigimod](https://longbridge.com/en/news/296077357.md)